BiomX Inc.

PHGE

US09090D1037

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:10:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.336 ^USD	-1.15%		+13.59%	+20.00%

Apr. 18	Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board	CI
Apr. 03	Transcript : BiomX Inc., Q4 2023 Earnings Call, Apr 03, 2024

BiomX Inc. announced that it has received $3 million in funding

October 24, 2021

On October 25, 2021, BiomX Inc. closed the transaction. The transaction included participation from 1 investor.

Latest news about BiomX Inc.

Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board	Apr. 18	CI
Transcript : BiomX Inc., Q4 2023 Earnings Call, Apr 03, 2024	Apr. 03
BiomX Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 03	CI
Biomx Inc. Announces Board Changes	Mar. 18	CI
BiomX Inc. announced that it has received $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC	Mar. 14	CI
BiomX Inc. completed the acquisition of Adaptive Phage Therapeutics, Inc.	Mar. 14	CI
Sector Update: Health Care Stocks Advance Wednesday Afternoon	Mar. 06	MT
Sector Update: Health Care	Mar. 06	MT
BiomX Shares Rally After Merger Deal With Adaptive Phage Therapeutics	Mar. 06	MT
Transcript : BiomX Inc., Adaptive Phage Therapeutics, Inc. - M&A Call	Mar. 06
BiomX Inc. announced that it expects to receive $50.013969 million in funding from Deerfield Management Company, LLC, AMR Action Fund GP, LLC, Cystic Fibrosis Foundation, Nantahala Capital Management, LLC, OrbiMed Advisors LLC	Mar. 05	CI
BiomX Inc. agreed to acquire Adaptive Phage Therapeutics, Inc. for $11.5 million.	Mar. 05	CI
BiomX Says Data From Phase 1b/2a Trial of BX004 Showed 'Meaningful' Improvement in Pulmonary Function	Nov. 29	MT
Transcript : BiomX Inc. - Special Call	Nov. 29
Biomx Announces Positive Topline Results from Part 2 of the Phase 1B/2A Trial Evaluating Bx004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis	Nov. 29	CI
BiomX Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Biomx to Present Data from Ongoing Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis	23-10-27	CI
BiomX Inc. Announces the Appointment of Edward L. Williams to its Board of Directors	23-10-18	CI
BiomX Inc. Announces Completion of Patient Dosing in Part 2 of Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis	23-10-04	CI
Transcript : BiomX Inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
BiomX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Biomx Inc. to Present Part 1 Data from Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session At The46th European Cystic Fibrosis Conference	23-05-31	CI
BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
HC Wainwright Cuts Price Target on BiomX to $7 From $10, Maintains Buy Rating	23-05-15	MT
Transcript : BiomX Inc., Q1 2023 Earnings Call, May 15, 2023	23-05-15

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).

Sector

Biotechnology & Medical Research

Calendar

2024-04-28 - ECCMID Meeting - Poster No - P2546

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.336 USD

Average target price

3 USD

Spread / Average Target

+792.86%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOMX INC.	+20.00%	18.55M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	103B
REGENERON PHARMACEUTICALS, INC.	+1.41%	95.71B
ARGENX SE	+0.73%	22.02B
BIONTECH SE	-17.84%	20.9B
GENMAB A/S	-9.00%	17.85B
WUXI APPTEC CO., LTD.	-42.83%	16.21B
BEIGENE, LTD.	-17.63%	15.52B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.86B
SAREPTA THERAPEUTICS, INC.	+32.11%	12.04B

Bio Therapeutic Drugs

BiomX Inc.

Equities

PHGE

US09090D1037

Biotechnology & Medical Research

BiomX Inc. announced that it has received $3 million in funding

Latest news about BiomX Inc.

Chart BiomX Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs